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Abstract
Spontaneous regression of advanced hepatocellular carcinoma is extremely rare. A 66-year-old
Taiwanese male patient with liver cirrhosis related to chronic hepatitis C presented with
hepatocellular carcinoma with portal vein thrombosis. At first, he refused curative therapy, except
for silymarin medicine. Spontaneous regression of hepatocellular carcinoma occurred with a decline
in tumour size and tumour marker in imaging studies. The patient agreed to undergo surgery
approximately 14 months after presentation because of no further decrease in tumour size and an
increase in tumour marker in the imaging studies. The resected tumour was hepatocellular carcinoma
with portal vein thromboses. Presently, the patient is alive and in good condition without any
symptoms or tumour recurrence. We concluded that this was a rare case of spontaneous regression
of advanced hepatocellular carcinoma.
Introduction
Primary hepatocellular carcinoma (HCC) is one of the
most common cancers, especially in Asia and Africa. It has
a high mortality rate and increasing incidence in the
world. Advanced HCC has a poor prognosis, and
untreated tumors show a rapidly fatal outcome, with a
median survival of 1.6 months [1]. However, spontaneous
regression of HCC is very rare and its mechanism is unclear
[2]. There is no curative therapy for advanced HCC [3].
Therefore, it has been suggested that HCC cases be given
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more attention. Here we present a rare case of a patient
with spontaneous regression of advanced HCC without
any curative therapy.
Case presentation
In March 2006, a 66-year-old Taiwanese male patient
complained of having upper right quadrant discomfort for
about 10 days. The patient also suffered frompoor appetite
and fatigue. His past history was significant with a traffic
accident and right leg amputation about 30 years ago. The
patient had no known exposure to chemicals, did not
drink, and smoked one pack per day for about 30 years. He
had gout disease and took analgesic medicine. Ultrasono-
graphy in our outpatient department revealed a large
tumour with central necrosis, measuring about 11 cm in
diameter, occupying the right lobe and left hydronephrosis.
Gastroscopy revealed pathology of active gastric ulcers
without Helicobacter pylori infection. In laboratory studies,
the patient had a high serum a-fetoprotein (AFP) level of
4280 ng/ml (normal range, 0-13.4 ng/ml) and a positive
hepatitis C antibody. We subsequently performed com-
puted tomography (CT) of the liver, which revealed a large
tumour with central necrosis, about 12 cm in diameter,
located in segments 7 and 8 of the right lobe (Figure 1),
along with left hydronephrosis and a ureter stone.
The CT scan also revealed tumour thrombus in the
posterior branches of the right portal vein (Figure 2).
According to Barcelona-Clinic Liver Cancer classification,
we made the diagnosis of HCC with portal vein
thrombosis [3]. However, the patient refused any invasive
therapy and examination for HCC, such as a biopsy,
surgery, radiofrequency ablation, or transcatheter arterial
chemoembolization (TACE). The patient agreed only to
treatment for left hydronephrosis and the ureter stone,
and the regular, oral administration of silymarin medicine
of 450 mg per day.
The patient was regularly followed-up in our outpatient
department with ultrasonography and examination of
serum a-fetoprotein levels. The tumour size gradually
decreased, and the a-fetoprotein level slowly declined
(Table 1) until December 2006. The patient did not take
any herbs or other curative or palliative therapy during the
HCC shrinkage.
CT scan of the liver was performed again and revealed
HCC regression, with tumour size reduced to about 4.6 cm
in diameter, and portal vein thrombosis (Figure 3).
Silymarin 450 mg daily was the only regularly prescribed
medicine during HCC reduction.
Nevertheless, the serum a-fetoprotein level increased
gradually from December 2006 (Table 1), and the tumour
size did not contract persistently as shown by abdominal
echo. We talked to the patient about his condition and
recommended surgery. The patient agreed to the surgery,
and we scheduled surgery for May 2007. CT scan of the
liver was performed prior to the surgery, revealing an HCC
size similar to the previous readings and portal vein
thrombosis. A total right lobectomy and cholecystectomy
were performed. The resected specimen in fresh state was a
Figure 1. CT scan of a large well-defined mosaic mass lesion
in right hepatic lobe with early contrast medium filling and
washout with central necrosis, measuring about 12 cm in
diameter.
Figure 2. Disturbance in contrast on posterior branches of
the right portal vein with portal vein tumour thrombosis.
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piece of liver tissue, measuring 14.5 × 7.5 × 6.2 cm in size;
330 g in weight; and brown with an uneven surface
macroscopically. On cuts, an ill-defined tumour, measur-
ing 6 × 4 × 3.5 cm in size, was observed at the subcapsular
area. The tumour was encapsulated, yellow, and soft with
a marked necrosis. Multiple satellite nodules, measuring
up to 1.7 × 1.5 × 1.5 cm in size, were observed. The
surrounding liver tissue was brown and cirrhotic. Histo-
logically, the viable tumour cells appeared as moderately
differentiated HCC with a trabecular and focal pseudo-
glandular pattern (Figure 4). Tumour thrombi were
located in the right posterior branch of the portal vein
(Figure 5). The tumour had central coagulative necrosis,
similar to a post-transcatheter arterial chemoembolization
(TACE) effect. The tumour extended into the subcapsular
area and was encapsulated by a thick, fibrous capsule.
The main tumour was surrounded by satellite nodules,
which were histologically similar to the main tumour.
The background liver had a non-neoplastic histology
of chronic hepatitis C with cirrhosis.
The postoperative course of this patient was smooth. The
serum a-fetoprotein level declined rapidly after the
operation, and it is currently at the normal level (Table 1).
Twenty months after the surgery, the patient is doing well
and has no signs of tumour recurrence.
Discussion
Spontaneous regression has been defined by Everson and
Cole as the partial or complete involution of a malignant
tumour without application of a specific therapy [2].
Spontaneous regression has been reported in a group of
malignant diseases, including HCC. However renal cancer,
neuroblastoma, and malignant melanoma are the main
types of tumours that have shown spontaneous regression
[4]. Spontaneous regression of HCC is a rare phenomenon.
Few reports of spontaneous regression of HCC have been
published in the English medical literature up to 2008 [5].
The pathogenesis of spontaneous regression is unclear.
Possible mechanisms proposed in the literature include
abstinence from alcohol consumption, taking herbal
medicine, arterioportal shunting, high fever, immune
system, androgen therapy, subintimal vascular injury by
angiographic procedures, rapid growth of tumour, gastro-
intestinal bleeding, administration of vitamin K, life style
modification, poor vascular circulation in cirrhosis,
vascular thromboses, and thick capsule [5]. Even on closer
examination of published cases on spontaneous regres-
sion of HCC, precise conclusions about the mechanisms
are difficult to derive. However, several authors have
suggested the possibility of an alternation in the vascular
supply and changes in the immune system.
Table 1. Serum a-fetoprotein (normal range 0-13.4 ng/ml)
Mar-2006 Nov-2006 Dec-2006 Feb-2007 May-2007 Jun-2007 Nov-2008
AFP 4280 717 546 724 1209 34.8 11.5
Figure 3. Right hepatic tumour shrinkage to about 4.6 cm in
diameter.
Figure 4. Histology of viable tumour cells, surrounded by
thick fibrous capsule, in a moderately differentiated
hepatocellular carcinoma (HCC) with trabecular and focal
pseudoglandular pattern.
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The histological findings of our patient, including the
tumour necrosis and the thick fibrous capsule, are similar
to findings of a post-TACE effect [6]. The inflammatory
cells, which infiltrated into the fibrous capsule and inside
of tumour, also suggest that the inflammatory reaction in
the patient was long-standing. Namely, it can be con-
cluded that changes in the immune system of the patient
were induced by vascular disturbance. The changes in the
vascular supply as well as in the immune system
demonstrate good anticancer effects.
Grossmann et al. reported a spontaneous regression of
HCC after the abstinence and administration of silymarin
[7]. Silymarin is a bioflavonoid antioxidant, and it is the
main constituent of Silybum marianum. Silymarin is
composed of silybin (also called silybinin, silybin, or
silibinin) with smaller amounts of other stereoisomers
such as isosilybin, dihydrosilybin, sildianin, and silychris-
tin [8]. Silymarin has a strong antioxidant property and is
capable of scavenging both free radicals and reactive
oxygen species [9]. In addition to silymarin’s antioxidant
effect, its anticancer effect in vitro has been certified by Lah
et al [1]. Although silymarin has been used for centuries,
its anticancer mechanism in HCC is still unknown. In
previous studies, possible mechanisms may have included
inhibition of extracellular signal-regulated kinase 1/2
phosporylation [11]; down-regulation expression of
cyclooxygenase-2 and attenuation hyperlipidemia [12];
inhibition of cytochrome P450 1A1 catalytic activity [13];
and inhibition of proliferation and induction of apoptosis
[14]. Our patient took silymarin regularly prior to surgery,
and he did not take any other herbs or medicines. Some
cases of regression have been associated with some herbal
medicines, but there is no conclusive evidence. However,
thus far, we have not clearly understood the effect and
mechanism of silymarin in HCC. Further studies are
needed to confirm these findings and to more fully
characterise the factors affecting HCC regression.
Conclusions
In summary, we report spontaneous regression of
advanced HCC in the case of a 66-year-old male patient.
Even after a literature review, spontaneous regression of
HCC are still unclear. It is possible that circulatory
disturbance and immune mechanisms may be major
pathways. Silymarin should be further investigated for its
anticancer effect. In conclusion, it is likely that treatment
of HCC in the future will include a multimodal
therapeutic method.
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